Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10882384 | 0.98 | TSHR (0.63) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| Hydrochloric Acid SCHEMBL2530402 | 0.96 | TSHR (0.61) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| Bromide SCHEMBL17957152 | 0.93 | TSHR (0.63) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL28739964 | 0.91 | TSHR (0.66) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| Bromide SCHEMBL11522116 | 0.89 | TSHR (0.55) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL1476239 | 0.87 | TSHR (0.57) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| SCHEMBL13415756 | 0.86 | TSHR (0.67) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| Hydrochloric Acid SCHEMBL475768 | 0.85 | TSHR (0.55) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| Bromide SCHEMBL28358221 | 0.85 | TSHR (0.61) | TSHRHPGDALDH1A1CYP3A4TP53 | |
| Bromide SCHEMBL27992109 | 0.84 | TSHR (0.59) | TSHRHPGDALDH1A1CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570860-B2 | Two-component treatment agent, treatment method for making metal surface antibacterial and antibacterial treatment agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| CN-119421788-A | Laminated film | 三菱化学株式会社 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024005216-A1 | LAMINATED FILM | 三菱ケミカル株式会社 | 2024-01-04 | — | — | WO | disclosed |
| EP-2367852-B1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | SEDERMA SA (FR) | 2023-08-30 | — | — | EP | disclosed |
| EP-3744729-B1 | PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES | SEDERMA SA (FR) | 2023-03-01 | — | — | EP | disclosed |
| US-20220267615-A1 | TWO-COMPONENT TREATMENT AGENT, TREATMENT METHOD FOR MAKING METAL SURFACE ANTIBACTERIAL AND ANTIBACTERIAL TREATMENT AGENT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| EP-2475349-A1 | CYCLOMETHICONE-FREE COSMETIC AND PERSONAL CARE PRODUCTS | Croda, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-1686957-B1 | COMPOSITIONS CONTAINING MIXTURES OF TETRAPEPTIDES AND TRIPEPTIDES | SEDERMA SA (FR) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011031392-A1 | CYCLOMETHICONE-FREE COSMETIC AND PERSONAL CARE PRODUCTS | CRODA, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| CN-1893911-B | Formula including tetrapeptide and tripeptide mixture | SEDERMA SA | 2010-12-29 | — | — | CN | disclosed |
| EP-1435978-A2 | ESTERS OF AROMATIC ALKOXYLATED ALCOHOLS AND FATTY CARBOXYLIC ACIDS | Croda, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1414397-A2 | ANTI-IRRITANTS | Croda, Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003063790-A2 | ADDITIVES AND PRODUCTS INCLUDING OLIGOESTERS | CRODA, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003060046-A1 | MIXTURES OF QUATERNARY COMPOUNDS | CRODA, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060048-A1 | IMMIDAZOLINE QUATS | CRODA, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003032919-A2 | ESTERS OF AROMATIC ALKOXYLATED ALCOHOLS AND FATTY CARBOXYLIC ACIDS | CRODA, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003013439-A2 | ANTI-IRRITANTS | CRODA, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| CN-1241932-A | Hair mousse composition comprising siloxane emulsion | PROCTER & GAMBLE (US) | 2000-01-19 | — | — | CN | disclosed |
| CN-1184419-A | Nonionic foaming agent for foaming cosmetic compositions | PROCTER & GAMBLE (US) | 1998-06-10 | — | — | CN | disclosed |
| CN-1184416-A | Foaming agent for leave-on foaming cosmetic compositions | PROCTER & GAMBLE (US) | 1998-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570860-B2 | Two-component treatment agent, treatment method for making metal surface antibacterial and antibacterial treatment agent | SARS1, ACE2, EIF2AK2 | CHRM2 3596/4885CHRM1 2671/4885CHRM3 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.